Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08WZQ
|
|||
| Drug Name |
MRG-201
|
|||
| Indication | Keloid [ICD-11: EE60; ICD-10: L73.0] | Phase 2 | [1] | |
| Scleroderma [ICD-11: 4A42; ICD-9: 701.0710.1] | Phase 1 | [2] | ||
| Company |
miRagen Therapeutics Boulder, CO
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Collagen (CO) | Target Info | Modulator | [2] |
| microRNA hsa-miR-155 (MIR155) | Target Info | Modulator | [2] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03601052) Efficacy, Safety, and Tolerability of Remlarsen (MRG-201) Following Intradermal Injection in Subjects With a History of Keloids. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.